Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Japan’s Toray Develops Biochip For 15-Minute Disease Detection

This article was originally published in PharmAsia News

Executive Summary

Toray Industries says it has developed a device that can cut the time for detecting the presence of cancer or other diseases from days to 15 minutes. Toray said its protein biochip, for which it plans to file an approval application by the end of the fiscal year, is capable of analyzing a single drop of blood for the presence of a disease. The company relied on nanotechnology to create a chip the size of a business card containing a tube for the blood, which can be read by an analyzer. (Click here for more - a subscription may be required

You may also be interested in...



E-cigarette NRT Outlook Heated By Combining With Counseling, Nicotine-Tapering Strategy

Results of three-year study conducted at 17 Canadian sites suggest that e-cigarettes use combined with counseling significantly increased abstinence from smoking cigarettes compared to receiving counseling alone.

Cambridge Nutraceuticals Targets Over 50s With UK Acquisition

Cambridge Nutraceuticals - which develops dietary supplements that have “proven clinical benefits” - has snapped up UK-based Prime Fifty to enhance its offering with products specifically designed for the over 50s.

Henlius Kicks Off Denosumab Trial

Shanghai Henlius Biotech has begun dosing in a Phase I trial for its HLX14 planned biosimilar version of denosumab. Multiple biosimilar developers are vying to take a slice of the market for rivals to Amgen’s Xgeva/Prolia original.

UsernamePublicRestriction

Register

SC143384

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel